RxDoctor Payments Data

Kevin Snyder, DO

Family Medicine · Flushing, MINPI 1578582391

Payments from drug & device makers

$11,668in general payments, 2019–2025

Across 698 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$1K
  • Novo Nordisk$1K
  • AstraZeneca$957
  • Lilly USA, LLC$843
  • Amgen$811
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$11,36497%
  • Education$3053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,668 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$64,146
Medicare patients
136
Services billed
14,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin123$150,125
EliquisApixaban144$129,631
MounjaroTirzepatide85$123,322
OzempicSemaglutide58$99,576
Repatha SureclickEvolocumab99$88,037
XareltoRivaroxaban48$56,099
FarxigaDapagliflozin Propanediol50$47,830
TrulicityDulaglutide24$39,777
JanuviaSitagliptin Phosphate34$38,113
VraylarCariprazine Hcl22$32,331
RybelsusSemaglutide16$29,342
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,834
TradjentaLinagliptin14$19,687
Janumet XrSitagliptin Phos/Metformin Hcl22$18,927
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$17,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$282$169,812137 claims
Lilly USA, LLCMounjaro, Trulicity$843$163,099109 claims
PfizerEliquis$433$129,631144 claims
Novo NordiskOzempic, Rybelsus$1,110$128,91874 claims
MerckJanuvia, Janumet Xr$85$57,04056 claims
Johnson & JohnsonXarelto$131$56,09948 claims
AbbVieVraylar, Linzess$1,345$48,53341 claims
AstraZenecaFarxiga$957$47,83050 claims
GSKTrelegy Ellipta, Anoro Ellipta$669$39,55138 claims
Otsuka America Pharmaceutical, Inc.Rexulti$150$17,06312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Flushing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →